Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.53 |
| ▸ | OTC | P00480 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 7/20 | 0.42 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | ARG2 | P78540 | 4/20 | 0.41 |
| ▸ | ARG1 | P05089 | 3/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24945952 | 1.00 | GSR (0.53) | GSROTCGNAI3GNAO1GNAI1 | |
| SCHEMBL22375753 | 1.00 | GSR (0.53) | GSROTCGNAI3GNAO1GNAI1 | |
| SCHEMBL20192790 | 0.95 | GSR (0.50) | GSROTCACHEDDAH1ARG2 | |
| SCHEMBL20192789 | 0.92 | GSR (0.56) | GSROTCGNAI3GNAO1GNAI1 | |
| SCHEMBL19246101 | 0.89 | GSR (0.56) | GSROTCGNAI3GNAO1GNAI1 | |
| SCHEMBL18924756 | 0.88 | GSR (0.53) | GSROTCACHEDDAH1ARG2 | |
| SCHEMBL19966765 | 0.87 | GSR (0.52) | GSROTCGNAI3GNAO1GNAI1 | |
| SCHEMBL23608137 | 0.86 | ACHE (0.53) | GNAI3GNAO1GNAI1ACHEDPP7 | |
| SCHEMBL23385458 | 0.86 | ACHE (0.53) | GNAI3GNAO1GNAI1ACHEDPP7 | |
| SCHEMBL23607693 | 0.86 | ACHE (0.53) | GNAI3GNAO1GNAI1ACHEDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338578-A1 | MODIFIED VIRAL PARTICLES FOR GENE THERAPY | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20230287383-A1 | PYRROLYSYL-tRNA SYNTHETASE VARIANTS AND USES THEREOF | ENGENES BIOTECH GMBH (AT) | 2023-09-14 | — | — | US | disclosed |
| US-20210290682-A1 | Functionalized Erythroid Cells | RUBIUS THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-11020435-B2 | Functionalized erythroid cells | RUBIUS THERAPEUTICS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| WO-2021035310-A1 | TARGETED DENDRIMER CONJUGATES | STARPHARMA PTY LTD (AU) | 2021-03-04 | — | — | WO | disclosed |
| US-20210024935-A1 | Read Through Of Truncated Proteins In Premature Termination Codon Diseases Using An Optimized Genetic Codon Expansion System | PEKING UNIVERSITY (CN) | 2021-01-28 | — | — | US | disclosed |
| US-20200268870-A1 | MUTANT VIRUS, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | PEKING UNIVERSITY (CN) | 2020-08-27 | — | — | US | disclosed |
| US-10253345-B2 | Cell lines | MEDIMMUNE LIMITED (GB) | 2019-04-09 | — | — | US | disclosed |
| US-9981908-B2 | Amino acid derivatives | MEDIMMUNE LIMITED (GB) | 2018-05-29 | — | — | US | disclosed |
| US-20170306381-A1 | CELL LINES | ALLOZYNE, INC. | 2017-10-26 | — | — | US | disclosed |
| US-9732367-B2 | Cell lines | MEDIMMUNE LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-9670521-B2 | Amino acid derivatives | MEDIMMUNE LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268870-A1 | MUTANT VIRUS, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | UPF1, CPSF7, CPSF1 | GSR 2114/4885OTC 1459/4885GNAI3 1038/4885 |
| US-20210290682-A1 | Functionalized Erythroid Cells | EPOR, TFRC, CD47 | GSR 139/4885OTC 2552/4885GNAI3 2203/4885 |
| US-10253345-B2 | Cell lines | AARS1, LARS1, IARS1 | GSR 1724/4885OTC 2174/4885GNAI3 4118/4885 |
| US-11020435-B2 | Functionalized erythroid cells | EPOR, TFRC, CD47 | GSR 139/4885OTC 2552/4885GNAI3 2203/4885 |
| US-20230338578-A1 | MODIFIED VIRAL PARTICLES FOR GENE THERAPY | HAVCR2, TMEM205, COPA | GSR 3216/4885OTC 2055/4885GNAI3 625/4885 |
| US-20170306381-A1 | CELL LINES | AARS1, LARS1, IARS1 | GSR 1724/4885OTC 2174/4885GNAI3 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.